Falcon Technologies Adds CBD Transdermal Sports Patch to Planned Product Line

SACRAMENTO, CA / ACCESSWIRE / May 9, 2019 / Falcon Technologies, Inc. (OTC PINK: FLCN), a company focused on the marketing, sale, and distribution of CBD products and products derived from industrial hemp announced today that in addition to plans to launch other dermal-delivered CBD products, the company will launch the “CBD Transdermal Sports Patch XR”.

Over the past few months, Falcon has filed two provisional patents and is also advancing the planned product line for acne, psoriasis and rosacea. These skin conditions represent a very large affected population within the United States.

Central to Falcon’s business plan is to develop CBD products that deliver therapeutic amounts of CBD with additional product formulation benefits to the customer. Falcon plans on releasing 2 extended release products. One will be a CBD transdermal sports patch. With the “CBD Transdermal Sports Patch XR”, CBD is released steadily and consistently over a 24-48 hour period. The other product is an oral extended release product which will release the complete CBD dose steadily over a 12-hour period. Falcon is currently engaged in discussions with 2 other publicly-traded companies regarding the oral product.

Universally known as CBD, Cannabidiol (the scientific name for CBD) is one of at least 80 active cannabinoids identified in both cannabis and industrial hemp. It is a major constituent of both plants, although the percentages of total composition can vary greatly from strain to strain. Unlike THC (the other prevalent cannabinoid), CBD is non-psychoactive while having the potential to possess a variety of therapeutic properties.

The 2018 Farm Bill legalized industrial hemp, removing this plant rich in CBD and nutritional supplements from the Controlled Substance Act and categorizing it as an agricultural commodity. This bill will allow states to regulate hemp farming while moving the industrialization of the hemp plant forward. As industrial hemp once again becomes one of America’s most popular agricultural crops, the amount of CBD processed from the plant will grow exponentially. The hemp-CBD market is projected to grow from $600 million in 2018 to $22 billion by 2022.

Over the past 2 months, CVS, one of North America’s largest drug store chains began selling topical CBD products.

William Delgado, Chairman and Chief Executive Officer of Falcon Technologies commented, “We are excited about this new product. It will have significant applications and patient use well beyond sports activities. Before we launch the product, we will review a lab analysis to make certain that the CBD dose is released steadily and consistently over the life of the patch. Products like this are potential CBD game changers.”

William Delgado concluded his comments by saying, “Falcon is currently engaged in discussions with 2 other publicly-traded companies regarding a planned extended release oral CBD. We expect to be able to provide an update within a few days.”

About Falcon Technologies, Inc. (a/k/a Eco-Growth Strategies, Inc.)

Falcon Technologies, Inc. (a/k/a Eco-Growth Strategies, Inc.) is a nutraceutical company developing a range of CBD-based products. The company’s mission is to employ best practice science to source, manufacture and package all of its CBD products from within the United States. The company performs farm site visits and manufacturing site visits and sources its products from only the highest quality hemp farms and processors in North America. The company also aims to launch a line of CBD products specially formulated for animals by the end of 2019.

CBD Disclaimer

The statements made regarding CBD products including our future products have not been evaluated by the Food and Drug Administration. The efficacy of these products and the testimonials made have not been confirmed by FDA- approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your healthcare professional about potential interactions or other possible complications before using any product. The Federal Food, Drug, and Cosmetic Act requires this notice.


Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: William J. Delgado
(775) 443-4740

SOURCE: Falcon Technologies, Inc.

View source version on accesswire.com:

error: Content is protected !!